Expression of pathogenic SCN9A mutations in the zebrafish: A model to study small-fiber neuropathy.
Nerve density
SCN9A mutations
Small-fiber neuropathy
Temperature assay
Zebrafish model
Journal
Experimental neurology
ISSN: 1090-2430
Titre abrégé: Exp Neurol
Pays: United States
ID NLM: 0370712
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
18
04
2018
revised:
21
09
2018
accepted:
10
10
2018
pubmed:
15
10
2018
medline:
11
4
2019
entrez:
15
10
2018
Statut:
ppublish
Résumé
Small-fiber neuropathy (SFN) patients experience a spectrum of sensory abnormalities, including attenuated responses to non-noxious temperatures in combination with a decreased density of the small-nerve fibers. Gain-of-function mutations in the voltage-gated sodium channels SCN9A, SCN10A and SCN11A have been identified as an underlying genetic cause in a subpopulation of patients with SFN. Based on clinical-diagnostic tests for SFN, we have set up a panel of two read-outs reflecting SFN in zebrafish, being nerve density and behavioral responses. Nerve density was studied using a transgenic line in which the sensory neurons are GFP-labelled. For the behavioral experiments, a temperature-controlled water compartment was developed. This device allowed quantification of the behavioral response to temperature changes. By using these read-outs we demonstrated that zebrafish embryos transiently overexpressing the pathogenic human SCN9A p.(I228M) or p.(G856D) mutations both have a significantly decreased density of the small-nerve fibers. Additionally, larvae overexpressing the p.(I228M) mutation displayed a significant increase in activity induced by temperature change. As these features closely resemble the clinical hallmarks of SFN, our data suggest that transient overexpression of mutant human mRNA provides a model for SFN in zebrafish. This disease model may provide a basis for testing the pathogenicity of novel genetic variants identified in SFN patients. Furthermore, this model could be used for studying SFN pathophysiology in an in vivo model and for testing therapeutic interventions.
Identifiants
pubmed: 30316835
pii: S0014-4886(18)30572-7
doi: 10.1016/j.expneurol.2018.10.008
pii:
doi:
Substances chimiques
NAV1.7 Voltage-Gated Sodium Channel
0
SCN9A protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-264Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.